Objective To investigate haptoglobin within ovarian cyst fluid (OCF) as a diagnostic biomarker for epithelial ovarian cancer (EOC) and develop an in vitro diagnostic point-of-care device test (IVDPCT) for use in the operating theatre.
Diagnostic accuracy of haptoglobin within ovarian cyst fluid as a potential point-of-care test for epithelial ovarian cancer: an observational study AP Main outcome measures Prediction of malignancy.
Results Haptoglobin concentration measured by ELISA was 0.70 AE 0.09 mg/ml in patients with benign cysts (n = 87), 6 .22 AE 0.53 mg/ml in early stage-EOC (n = 17), and 6.57 AE 0.65 mg/ml in late stage-EOC (n = 20). Haptoglobin in EOCs was significantly higher than in benign cysts (P < 0.0001). Haptoglobin using rapid colorimetric assay (RCA) on a training set had a sensitivity of 97.3% and a specificity 92.0%, comparable to ELISA and frozen sections. The haptoglobin AUROC curve was 0.999 (95% CI 0.997-1.000) compared with 0.895 (95% CI 0.814-0.977, P < 0.05) for CA125. Haptoglobin performed significantly better than all the RMIs (P < 0.01). Blinded validation studies showed a minor drop in average diagnostic performance (sensitivity 85.2% and specificity 90.5%) compared with the training set. However, when compared with frozen section, haptoglobin was no worse in diagnostic accuracy for malignancy.
Introduction
Epithelial ovarian cancer (EOC) is a disease with a poor prognosis. The lifetime risk of developing EOC is 1.4%, and worldwide 239 000 new cases are diagnosed annually. 1 Two key factors that could improve survival in EOC are early diagnosis and appropriate primary surgery. 2 Most patients are diagnosed at late stage (LS-EOC), when the tumours respond poorly to therapy and have metastasised. 3 Consequently, 5-year survival rates are only 40%. 4 In contrast, patients diagnosed with early-stage EOC (ES-EOC) have 5-year survival rates >90%. 5 There have been attempts to define symptoms that warrant earlier investigation; however, EOC symptom-complexes have low positive-predictive values (PPV) for ES-EOC 6 , and one in six ES-EOC patients are asymptomatic. 7 No clinically proven effective screening exists. 8 There may be a role for a multimodal screening; 9 however, the value of screening in lowering mortality may only be realised after protracted close surveillance. 4 Benign ovarian cysts are common 10 and the relative preponderance of cancers versus benign cysts varies. 4, 11, 12 The natural history of cysts remains poorly understood. 9, 13 Laparoscopy or laparotomy is the standard surgical approach for benign ovarian masses, 8 but in up to 14%, an unexpected malignancy is encountered. 13 Preoperative prediction of the malignant potential remains challenging in early stage disease. This is especially true for ovarian masses identified in premenopausal women, and in South-East Asian countries, where the incidence of EOC rises in women in their 30s. 8, [14] [15] [16] Intra-operative frozen section (FS) has been proposed to prevent delay in primary surgery, 17 but suffers from several limitations such as wide variation in accuracy due to large size of cysts, sampling error, and limitation of available staining methods owing to time constraints. 18, 19 Our preclinical exploratory proteomic studies demonstrated the presence of haptoglobin within the OCF that was able to differentiate between benign ovarian tumours, borderline and EOC (detailed in Results and Supporting Information Appendix S1). As an acute phase reactant protein, serum haptoglobin concentrations rise in many cancers, but with poor sensitivities and specificities. In contrast, we showed through tissue microarray studies that haptoglobin within OCF accurately reflects the benign and malignant nature of the ovarian cystic masses, as it is produced and concentrated locally within the cancer (detailed in Results).
We hypothesised that haptoglobin may be of potential use as an in vitro diagnostic tool in the development and validation of a clinical assay using retrospective and prospective clinical samples.
Materials and methods

Subject recruitment and sample collection
We recruited 324 patients ( Figure 1A) , between the ages of 11 and 74 years from December 2003 to March 2014 undergoing either laparoscopy or laparotomy for clinically suspicious tumours of the ovary at our local academic medical centre (LMC) and from five hospitals in Indonesia and Vietnam (regional medical centres, RMCs).
Our local academic medical centre recruited 284 patients (172 benign, 30 borderline and 82 malignant tumours), a combination of retrospective and prospective cohorts. In our retrospective cohort, we collected and archived ovarian cyst fluid from 184 patients. The histopathology diagnoses (frozen section, when conducted, and paraffin) for the 184 samples were known during selection for the type(s) of analysis that were performed. Retrospective sampling was performed to facilitate batch testing in laboratory investigations (preclinical and assay development phase). Prospective consecutive sampling was performed in 100 patients and analysed without any prior knowledge of the histopathology diagnosis (prospective validation phase). The RMC recruited 40 patients, and these samples were combined with our local retrospective cohort (31 benign tumours and nine malignant tumours). In aggregate, they represented 17.9% of the whole retrospective cohort used.
The National Healthcare Group Domain Specific Review Board approved local collection and use of patient samples, and the local ethics committee at each regional centre gave corresponding approval. All patients provided written informed consent. All tumours were defined by histopathological diagnoses (reference standard) and staging was according to the International Federation of Gynecology and Obstetrics (FIGO) staging for ovarian cancer. 20 Ovarian dermoid cysts, endometriotic cysts, pelvic inflammatory disease, tubo-ovarian abscesses, solid and frank malignant tumours were excluded from this study.
Ovarian cyst fluid samples were collected either at laparoscopy or laparotomy without spillage into the abdominal cavity. At laparotomy, the intact cyst was removed from the abdominal cavity followed by immediate aspiration of cyst contents via a syringe. At laparoscopy, the cyst was contained within an endobag and aspiration of the cyst was performed either from the endobag before, or after being removed from the abdominal cavity. OCFs that were heavily contaminated with blood were excluded as they contain haptoglobin and haemoglobin, which would interfere with our haptoglobinbased test. Retrospective samples were transported on ice to the laboratory, centrifuged at 2000 9 g for 10 minutes at 4°C and the supernatant stored in À80°C until analysis. Prospective samples were kept on ice and analysed immediately, not exceeding 4 hours post-cyst aspiration.
Measurement of haptoglobin concentrations by ELISA and rapid colorimetric assay (RCA) on retrospective samples
The OCF haptoglobin concentrations were measured in benign tumours, ES-and LS-EOCs using ELISA (Appendix S1) on 144 retrospective OCF samples ( Figure 1A ). Histopathological classifications of all tumours (reference standard) and FIGO stages of malignant cases are detailed in Supporting Information Tables S1 and S2. We used an RCA, and semiquantitatively measured haptoglobin concentrations on the same retrospective cohort (Appendix S1). A receiver operating characteristic (ROC) SDS-PAGE-sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SELDI-surface-enhanced laser desorption/ionization; LMC-local medical centre; RMC-regional medical centres; ELISA-enzyme-linked immunosorbent assay; RCA-rapid colorimetric assay; ROC-receiver operating characteristics; RMI-risk of malignancy index; IVDPCT-in vitro diagnostic point-of-care test B e n i g n E a r l y c a n c e r L a t e c a n c e r A l l c a n c e r At a haptoglobin cut-off level of 2.85 mg/ml the sensitivity was 97.3% (95% CI 84.2-99.9%), specificity was 97.7% (95% CI 91.1-99.6%), PPV was 94.7% (95% CI 80.9-99.1%) and NPV was 98.8% (95% CI 92.8-99.9%), at a prevalence of 3:2 benign to malignant cases.
curve was used to obtain haptoglobin cut-off concentrations (data not shown).
Comparing OCF haptoglobin with CA125 and risk of malignancy indices (RMIs) for prediction of malignancy
Preoperative ultrasound reports and CA125 levels of patients recruited from LMC (Supporting Information  Table S3 ) were obtained and evaluated for the risk of ovarian cancer by calculating three RMIs (RMI 1 21 , RMI 2 22 and, RMI 3 23 ; Appendix S1).
Validation of OCF haptoglobin in blinded retrospective and prospective real-time samples
We performed validation studies on 150 OCF samples (Figure 1A, n = 50 retrospective and n = 100 prospective) in 96-well plate format (index test) (RCA) and IVDPCT format (index test) (RCA in IVDPCT; Development of IVDPCTAppendix S1, Supporting Information Figure S3 ) both in the laboratory and in the operating theatre (Appendix S1). The reference/gold standard for diagnosis of all tumours was tissue histopathology. Independent testers performed the index tests in the laboratory and operating theatre. The IVDPCT testers received training on IVDPCT use. Testers watched a training video of IVDPCT use followed by a live demonstration of the IVDPCT. Next, the testers performed practicals using the IVDPCT with known haptoglobin controls.
Statistical analysis
We tested data for normality with D'Agostino's K 2 -test, and evaluated statistical significance with Student's t-test (two-tailed) for comparison of age and peak intensity; Mann-Whitney U-test (two-tailed) for comparison of serum CA125 level, tissue expression of haptoglobin, and OCF haptoglobin concentration; and Fisher's exact test (two-tailed) or Pearson's chi-square test for comparison of the proportions of patients present with each ultrasound feature or score between benign and malignant EOCs. We used ROC curves to assess the performance of biomarkers and evaluated the statistical significance for the comparison of two areas under the curve. 24 We used nonparametric Spearman and Bland-Altman for RCA and IVDPCT correlation tests. All statistical analyses were performed using GraphPad PRISM 5.03 (GraphPad Software, La Jolla, CA, USA) and MEDCALC v11.2.1.0 (MedCalc Software bvba, Mariakerke, Belgium). We expressed data as mean AE SEM and considered results statistically significant at P < 0.05.
Results
The results are presented in three phases: Preclinical Exploratory, Clinical Assay Development, and Prospective Validation studies.
Preclinical exploratory phase
We present results of haptoglobin, a potential biomarker within OCF, identified through proteomics (mass spectrometry, SDS-PAGE, SELDI Western blot) and immunocytochemical (tissue microarray) methods.
We analysed retrospective OCF ( Figure 1A ) from benign ovarian tumours, ES-EOCs and LS-EOCs with SELDI-TOF/ MS in mass ranges 7-60 kDa and identified a high-intensity discriminatory peak at 17.5 kDa that varied in proportion according to the extent of malignancy. It was present in 9/10 LS-EOCs, but absent/present at very low intensities in benign tumours. In early-stage disease, this peak was intermediate between benign and late-stage disease (Supporting Information Figure S1A ). Haptoglobin identity was confirmed by SDS-PAGE, peptide sequence matching, SELDI and Western blot (Appendix S1, Figures S1B-F and S2A,B).
Using immunohistochemistry on tissue microarray (TMA) slides, we observed strong expression within the epithelial lining cells of EOC and absent/weak expression of haptoglobin in the epithelial linings of normal ovaries and benign ovarian cysts ( Figure S2C ). These images were converted to grey-scale luminosity grading. Here we showed that cancerous cells had significantly higher levels of haptoglobin expression than seen in benign tumour cells (P < 0.0001) ( Figure S2D ), and borderline cells had intermediate staining.
Clinical assay development phase
We present ELISA (quantitative) and rapid colorimetric assay (semiquantitative) measurements of haptoglobin in benign, borderline, ES-and LS-EOCs. Result of operating characteristics of haptoglobin versus CA125 and RMIs is shown. Results of assay optimisation, observer bias study and reproducibility in 96-well plate and IVDPCT are presented.
Detection of OCF haptoglobin concentration by ELISA and RCA The OCF haptoglobin concentration detected by ELISA in women with ES-or LS-EOC (6.22 AE 0.53 and 6.57 AE 0.65 mg/ml, respectively, P > 0.05) was significantly higher than in women with benign tumours (0.70 AE 0.09 mg/ml) (P < 0.0001), although there was no significant difference in haptoglobin concentrations between ES-EOCs and LS-EOCs ( Figure 1B) . Among women diagnosed with ES-EOC, five had serous carcinoma subtype [three low/intermediate-grade and two high-grade serous carcinoma (HGSC)]. In all these samples, haptoglobin concentrations (range 3.9-7.3 mg/ml) were higher than the cut-off value (2.85 mg/ml). The accuracy of RCA (at cut-off 0.5 mg/ml) was similar to that of ELISA (at cutoff 2.85 mg/ml) (Table 1) as determined using CA, cancer; Non-CA, non-cancer; NPV, negative predictive value; PPV, positive predictive value. *Haptoglobin at cut-off 2.85 mg/ml. **Haptoglobin at cut-off 0.5 mg/ml.
retrospective OCF samples (n = 124; Figure 1A , Table S1 ). Using an ELISA-based assay, haptoglobin has an overall sensitivity of 97.3% and an NPV of 98.8% (Table 1) . When considering only retrospective regional medical centre samples, in resource-challenged countries, the sensitivity and NPV are 88.9 and 96.9%, respectively. Using an RCA where the results could be ready in 5 minutes inside the operating theatre, the overall sensitivity and NPV were 97.3 and 98.8%, respectively ( (Table 2A) . Three cases (9.1%) had an FS diagnosis discordant with the histopathology. FS misdiagnosed one ES-EOC as benign (false negative), and two benign tumours as borderline tumours (false positives). In contrast, in one case (3.0%) OCF haptoglobin measurements using ELISA and in two cases using RCA (6.1%) were discordant with histopathology. All discordant cases were benign tumours that were over-diagnosed. Overall, sensitivity, specificity, PPV and NPV of both methods of detecting OCF haptoglobin were similar to FS (Table 2A) .
OCF haptoglobin is more accurate than CA125 or RMIs Risk malignancy indices is used frequently in the preoperative triage of patients with ovarian cysts. Menopause status is one key discriminant used in this risk calculation. In the Caucasian population, >80% of EOC patients are postmenopausal. In our local academic medical centre cohort, the mean ages for the benign and malignant groups were 39.6 AE 13.9 and 51.5 AE 10.0, years, respectively (P < 0.0001), but 50% (14/28) of patients with cancer were premenopausal, which led to lower RMI scores (Table S3 ). Another key component of the RMI is the CA125 concentration. In our cohort, 10% of women with benign cysts had elevated CA125 concentrations and 14.3% of patients with malignant disease had a CA125 < 35 U/ ml. Using an ROC curve analysis ( Figure 1C) , we show that haptoglobin had superior diagnostic efficiency (AUC 0.999, 95% CI 0.997-1.000) compared with CA125 (AUC 0.895, 95% CI 0.814-0.977; percentage D = 10.4%; P = 0.013). Three versions of the RMI have been used, which are similar in principle (menopausal status, ultrasound features and CA125 concentrations) but differ in the weights of each element: RMI 1 21 , RMI 2 22 and, RMI 3 23 . Here, too, haptoglobin out-performed all three RMIs ( Figure 1C ).
Assay optimisation, observer bias study and reproducibility in 96-well plate and IVDPCT
In the laboratory, we tested RCA in 96-well plates (Figure S4 ) and IVDPCT formats ( Figure S3 ) using 50 retrospective samples ( Figure 1A , Supporting Information Table S5 ) where the testers were blinded to the histopathology diagnoses (Appendix S1). The IVDPCT was in agreement with that of 96-well plate, as indicated by absorbance (630 nm) (Spearman's slope = 1.25, R 2 = 0.961; Bland-Altman (BA) bias = À0.08) (Figure S5A,B) . There was no significant difference between the mean absorbance for the 96-well and for the IVDPCT (P > 0.05; Supporting Information Table S4 ). There was no interobserver difference in the discrimination of visual colour appearance between the 96-well and IVDPCT (BA bias = 0; Figure S5C ) and good agreement of visual calls compared with histopathology diagnoses (BA bias = 0.01; Figure S5D ) with a sensitivity of 100%, a specificity of 96.8%, PPV 95%, and NPV 100% (Table 3) .
Prospective validation phase
We present sensitivity, specificity, PPV and NPV results of 100 prospective blinded OCF sample assayed in the laboratory and operating theatre.
Fifty consecutive prospective blinded samples were collected at surgery for ovarian cyst and tested in the laboratory using the RCA (index test) ( Figure 1A ) and compared with histopathology diagnosis (reference standard; Table S5 ). We observed a sensitivity of 85.7% (95% CI 62.6-96.2%), a specificity of 89.7% (95% CI 71.5-97.3%), PPV of 85.7% (95% CI 62.6-96.2%), and NPV of 89.7% (95% CI 71.5-97.3%) ( Table 3) .
We followed this up with a prospective blinded study of the IVDPCT (index test) with 50 OCF consecutively sampled and tested real-time ( Figure 1A ) in the operation theatre with the IVDPCT tester blinded to the type of surgery performed and diagnosis. We recorded visual calls from the IVDPCT and compared these with FS and histopathology (reference standard obtained 1-2 weeks post-surgery; Table S5 ). The IVDPCT had a sensitivity of 70% (95% CI 35.4-91.9%), a specificity of 85% (95% CI 69.5-93.8%), PPV of 53.8% (95% CI 26.1-79.6%), and NPV of 91.9% (95% CI 77-97.9%) ( Table 3) . Of the 50 IVDPCT cases tested in theatre, 26 had FSs performed, with 22 benign and four cancerous cases as confirmed by histopathology. The overall accuracy in determination of the status of malignancy was 92.3% for IVDPCT compared with 88% for FS (Table 2B ). Three cases (11.5%) had an FS diagnosis discordant with histopathology and one FS without a diagnosis due to technical difficulties during tissue cryosectioning (IVDPCT result matched histopathology). Three benign tumours were misdiagnosed: one low-grade neoplasm and two borderline tumours (false positives). In contrast, two cases (7.7%) by IVDPCT had OCF haptoglobin measurements discordant with histopathology. All discordant cases were benign tumours that were over-diagnosed (false positives). Overall diagnostic performance was higher in IVDPCT than FS (Table 2B) .
Discussion
Main findings
We demonstrated the presence of haptoglobin in OCF of benign, borderline and malignant EOCs. The concentration of haptoglobin was significantly raised in ES and LS-EOC IVDPCT, in vitro diagnostic point-of-care test device; NPV, negative predictive value; PPV, positive predictive value. *Haptoglobin at cut-off 2.85 mg/ml. **Haptoglobin at cut-off 0.5 mg/ml. ***One FS did not provide a diagnosis due to technical difficulties during cryosectioning, but IVDPCT and histology results were in agreement.
compared with benign tumours. We also observed raised haptoglobin concentrations in OCF of low-volume HGSCs. Semiquantitative measurements of haptoglobin using an RCA in clinical assay development gave diagnostic accuracies similar to ELISA and frozen section. The haptoglobin AUROC curve was 0.999 (95% CI 0.997-1.000) compared with 0.895 (95% CI 0.814-0.977, P < 0.05) for CA125. Haptoglobin performed significantly better than all the RMIs (P < 0.01). We showed good correlation between the RCA and IVDPCT and minimal intra-and interobserver bias.
In our prospective validation study, the diagnostic accuracy of IVDPCT was marginally poorer than that of the assay development tests, but it does maintain accuracy comparable to FS.
Strengths and limitations
Several studies exploring OCF for biomarker analysis found it to have little use for discriminating between benign and malignant tumours. 25, 26 One study suggested that OCF contained tumour-specific biomarkers, 25 but this study had several limitations. The putative biomarkers identified by protein profiling were not confirmed by analysis of the exact peptide sequence; none of the peaks were superior to CA125 used alone; and a 1:1 ratio of benign versus malignant samples was used, leading to a discovery strategy that would yield low PPVs. 27 In our analysis of haptoglobin concentrations in 324 OCF samples, we found haptoglobin was able to differentiate benign from malignant EOCs with high accuracy. Only haptoglobin within borderline ovarian tumour samples showed poorer diagnostic accuracy for malignancy when compared with FS, and the accuracy of haptoglobin was only marginally better than that of CA125 or RMI1 (Table S2) . A recent Cochrane review highlighted similar problems with the accuracy of frozen section in the diagnosis of borderline ovarian tumours. 19 This validated our FS findings of poorer accuracy (80%) in borderline ovarian tumours when compared with paraffin histopathology (Table S2) .
Tissue microarray study of 141 ovarian tissue samples showed that haptoglobin accumulation within ovarian cyst fluid is more reflective of the biological changes within the tumour microenvironment compared to haptoglobin in serum. Although the pathophysiology of haptoglobin overexpression within malignant cysts remains unclear, we showed specific overexpression within the epithelial lining cells of cancerous cysts ( Figure S2C ). Although some investigators have shown the presence of haptoglobin-1 precursor (HAP1) within ovarian cancer cells, 28 other acute phase reactants reportedly are raised in HGSCs. 29 Unlike the RMIs, haptoglobin-based segregation for malignancy was independent of the patient's menopausal status. Here, haptoglobin performed significantly better Table 3 . Sensitivity, specificity, PPV and NPV of cyst fluid haptoglobin determined by RCA and IVDPCT in the differential diagnosis of benign and malignant epithelial ovarian tumours in 150 blinded samples: clinical assay development phase (n = 50) and prospective validation phase (n = 100)
IVDPCT in lab (n = 50) IVDPCT in theatre (n = 50) than CA125 either used alone or as part of the RMIs. This is because in the Western hemisphere, EOC is a disease mainly of postmenopausal women. 21 In contrast, half of the women with EOC in our study were premenopausal. This is in keeping with national data from Singapore (National Cancer Registry) and with our own hospital data collected over 3 years, suggesting an earlier rise in the incidence of EOC locally and regionally. [14] [15] [16] The sensitivity of RMI1 for adnexal masses in this local hospital cohort of Asian patients is only 54%. Recent use of the IOTA risk prediction model has shown a higher accuracy than RMI in both pre-and postmenopausal women, but still does not remove the need for intraoperative diagnostics in the evaluation of suspicious ovarian tumours. 30 Epithelial ovarian cancer prevalence in our study ranged between 20% and 42%, which reflects clinical practice, as there are greater numbers of benign than malignant cases undergoing investigation. Even with the increased number of benign samples tested, haptoglobin gave high positive predictive values (PPVs) (range 83.7-94.7%) in all OCF samples. Typically, estimates of diagnostic performance in the validation samples are more realistic (and lower) than in the clinical assay development samples and this is seen in the lowered diagnostic performance of the validation samples. Due to the smaller sample size and lower prevalence of EOC, the confidence interval for the validation set is wider than for the assay development samples.
Interpretation
In our study, haptoglobin and FS seem to have comparable diagnostic accuracies. Sensitivity of FS varies between 65 and 97%, with specificities of 97-100% according to a meta-analysis. 18 Factors contributing to this wide variation in accuracy include large size of cysts, sampling error, and limitation of available staining methods owing to time constraints. 18, 19 The overall utility of FS is even worse because of additional logistical limitations, and it can create inefficiency in operating room utilisation, with surgeries stopping for >30 minutes, increasing patient morbidity. Haptoglobin, however, has the additional benefit of being a rapid, easy and cost-efficient diagnostic test to perform at the patient's point-of-care.
The IVDPCT is intended for use in women undergoing surgical investigation for a suspicious cystic mass, as a triage for FS, or even as a surrogate for FS in resource-challenged countries where FS is not available. In a test with a high NPV, such as this one, if the IVDPCT were negative, we could avoid FS and complete the surgery; a true positive test would require either an FS or involvement of gynaecologic oncologists if FS were not readily available. Initial surgery performed by a gynaecologic oncologist is associated with accurate staging, complete resection of disease and improved patient prognosis.
31,32
Conclusion and research recommendations
The present study is the first demonstration of OCF haptoglobin as a highly discriminatory biomarker between benign and malignant EOCs. Larger prospective blinded clinical studies are required to determine the operating characteristics of the IVDPCT in a relevant population to determine detection and false negative rates. Larger trials are also needed to identify malignant cases and select benign cases that would not require FS evaluation. Our data suggest the potential utility of OCF haptoglobin as an in vitro diagnostic point-of-care tool with accuracy comparable to that of frozen section.
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